▲ Peaking
Business
Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
Endeavor's Phase IIb IPF study yields positive results, setting stage for potential Phase III trial.
Phase Iii
5 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Phase Iii
This hub groups 5 separate news trends connected to Phase Iii, spanning September 2, 2026 through October 9, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 48 article observations and 47 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
10 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✗
Psychedelics Stock, Up 190% This Year, Flies High Again
12 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
◼ Archived
Business
🔮 holds ✗
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis’s Rhapsido clears two Phase III hurdles, sending its stock soaring.